Activity of systemic therapies after cabozantinib (CABO) in patients (pts) with metastatic renal cell carcinoma (mRCC)

被引：1
|
作者：
Cerbone, L. [1 ]
Di Nunno, V. [2 ]
Carril, L. [1 ]
Benchimol-Zouari, A. [1 ]
Flippot, R. [1 ]
Silva, C. Alves Costa [1 ]
Colomba-Blameble, E. [1 ]
Guida, A. [3 ]
Derosa, L. [1 ]
Escudier, B. [1 ]
Albiges, L. [1 ]
机构：
[1] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[2] Osped Bellaria, Oncol Med, Bologna, Italy
[3] Osped Santa Chiara Terni, Med & Traslat Oncol, Terni, Italy
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.815
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
743P
引用
收藏
页码：S577 / S577
页数：1
相关论文
共 50 条
  • [41] Impact of microbiome modulation on serum cytokine profile in a randomized, phase I trial of cabozantinib/nivolumab (cabo/nivo) with or without CBM588 in pts with metastatic renal cell carcinoma (mRCC)
    Li, Yu Jun
    Ebrahimi, Hedyeh
    Meza, Luis
    Malhotra, Jasnoor
    Li, Xiaochen
    Dizman, Nazli
    Dorff, Tanya
    Frankel, Paul
    Llamas-Quitiquit, Marian
    Hsu, JoAnn
    Zengin, Zeynep
    Alcantara, Marice
    Castro, Daniela
    Mercier, Benjamin
    Chawla, Neal
    Chehrazi-Raffle, Alexander
    Barragan-Carrillo, Regina
    Gillece, John
    Trent, Jeffrey
    Lee, Peter
    Parks, Thomas
    Takahashi, Motomichi
    Hayashi, Atsushi
    Caporaso, J. Gregory
    Lee, Keehoon
    Tripathi, Abhishek
    Pal, Sumanta
    ONCOLOGIST, 2024, 29 : S36 - S37
  • [42] Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience
    Matrana, Marc Ryan
    Shetty, Aditya V.
    Atkinson, Bradley J.
    Xiao, Lianchun
    Corn, Paul G.
    Millikan, Randall E.
    Jonasch, Eric
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
    Gruenwald, Viktor
    Merseburger, Axel S.
    ONCOTARGETS AND THERAPY, 2012, 5 : 111 - 117
  • [44] Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with metastatic renal cell carcinoma (mRCC).
    Marteau, Florence
    Harrow, Brooke
    McCarthy, Christine
    Wallace, Joel
    Monnette, Alisha
    Wang Yunfei
    Doshi, Gurjyot K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [45] Active surveillance (AS) as potential treatment modality for management of patients (pts) with metastatic renal cell carcinoma (mRCC)?
    Ivanyi, P.
    Eggers, H.
    Seidel, C.
    Ganser, A.
    Gruenwald, V
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 320 - 320
  • [46] A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
    Jac, J.
    Giessinger, S.
    Khan, M.
    Willis, J.
    Chiang, S.
    Amato, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Evaluation of safety, tolerability and activity of Temsirolimus in patients (pts) with advanced or metastatic renal cell carcinoma (a/mRCC) in routine clinical practice
    Woike, M.
    Bergmann, L.
    Steiner, T.
    Goebell, P. J.
    Goehler, T.
    Harich, H. -D
    Herrmann, E.
    Rebmann, U.
    Kalanovic, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 88 - 88
  • [48] Hypertension and myelosuppression as biomarkers of sunitinib efficacy in Chinese patients (pts) with metastatic renal cell carcinoma (mRCC)
    Qin, Shukui
    Jin, Jie
    Guo, Jun
    Wang, Jin-Wan
    Zhou, Fang-Jian
    Huang, Yi-Ran
    Ren, Xiu-Bao
    Ye, Ding-Wei
    Pan, Sharon
    Sajben, Peter
    Wang, Qiao
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [49] Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Feldman, D. R.
    Kondagunta, G. V.
    Ronnen, E. A.
    Fischer, P.
    Chang, R.
    Baum, M.
    Ginsberg, M. S.
    Ishill, N.
    Patil, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] Tumor response is an independent prognostic factor in patients (pts) treated for metastatic renal cell carcinoma (mRCC)
    Gruenwald, V.
    Lin, X.
    Kalanovic, D.
    McKay, R.
    Perkins, J.
    Simantov, R.
    Choueiri, T.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S642 - S642
12345